瑞德西韦是否应该用于治疗 COVID-19 患者？美国医师学会的快速、实用实践要点（第 2 版）。
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).
机构信息
American College of Physicians, Philadelphia, Pennsylvania (A.Q., I.E.).
American College of Physicians, Philadelphia, and Villanova University, Villanova, Pennsylvania (J.Y.).
出版信息
Ann Intern Med. 2021 May;174(5):673-679. doi: 10.7326/M20-8101. Epub 2021 Feb 9.
Abstract
Clinicians must have access to the best available evidence to inform point-of-care decisions about the use of remdesivir in patients with COVID-19. This article provides updated advice from the American College of Physicians for clinicians based on an updated rapid review.
摘要
临床医生必须能够获得最佳可用证据，以便在 COVID-19 患者的护理点决策中使用瑞德西韦。本文根据一项更新的快速审查，为临床医生提供了美国医师学院的最新建议。
相似文献
1
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).瑞德西韦是否应该用于治疗 COVID-19 患者？美国医师学会的快速、实用实践要点（第 2 版）。
Ann Intern Med. 2021 May;174(5):673-679. doi: 10.7326/M20-8101. Epub 2021 Feb 9.
2
Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).最新警报2：瑞德西韦是否应用于治疗新型冠状病毒肺炎患者？美国医师协会的快速实用要点（第2版）
Ann Intern Med. 2021 Dec;174(12):W116-W117. doi: 10.7326/L21-0607. Epub 2021 Oct 5.
3
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).瑞德西韦是否应用于治疗 COVID-19 患者？美国医师学会的快速实践要点（第 1 版）。
Ann Intern Med. 2021 Feb;174(2):229-236. doi: 10.7326/M20-5831. Epub 2020 Oct 5.
4
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
5
Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.瑞德西韦用于治疗COVID-19的孤儿药指定的政策影响
JAMA Intern Med. 2020 Oct 1;180(10):1273-1274. doi: 10.1001/jamainternmed.2020.2759.
6
Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process.瑞德西韦的紧急使用授权：透明分配流程的必要性。
JAMA. 2020 Jun 16;323(23):2365-2366. doi: 10.1001/jama.2020.8863.
7
Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points.主要更新：瑞德西韦治疗成人 COVID-19：美国医师学会实践要点的实时系统评价和荟萃分析。
Ann Intern Med. 2021 May;174(5):663-672. doi: 10.7326/M20-8148. Epub 2021 Feb 9.
8
Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?我们用瑞德西韦（一种老药新包装）找到了治疗新冠病毒肺炎的万灵药了吗？
J R Coll Physicians Edinb. 2020 Jun;50(2):159-161. doi: 10.4997/JRCPE.2020.217.
9
[Remdesivir for patients with COVID-19].[瑞德西韦用于新型冠状病毒肺炎患者]
Internist (Berl). 2020 Aug;61(8):869-872. doi: 10.1007/s00108-020-00836-7.
10
Experts Discuss COVID-19-Remdesivir, Vaccines, and More.专家探讨新冠病毒——瑞德西韦、疫苗及其他相关话题。
JAMA. 2020 Aug 25;324(8):730-731. doi: 10.1001/jama.2020.15067.
引用本文的文献
1
Reimagining How We Synthesize Information to Impact Clinical Care, Policy, and Research Priorities in Real Time: Examples and Lessons Learned from COVID-19.重新构想我们如何实时综合信息以影响临床护理、政策和研究重点：来自 COVID-19 的实例与经验教训
J Gen Intern Med. 2024 Oct;39(13):2554-2559. doi: 10.1007/s11606-024-08855-y. Epub 2024 Jun 26.
2
Therapeutic strategies for COVID-19: progress and lessons learned.COVID-19 的治疗策略：进展与经验教训。
Nat Rev Drug Discov. 2023 Jun;22(6):449-475. doi: 10.1038/s41573-023-00672-y. Epub 2023 Apr 19.
3
Guidelines for the prevention and management of children and adolescents with COVID-19.儿童和青少年 COVID-19 防治指南。
Eur J Pediatr. 2022 Dec;181(12):4019-4037. doi: 10.1007/s00431-022-04615-4. Epub 2022 Sep 16.
4
Clinical research methodology process: what is changing with COVID-19?临床研究方法学流程：新冠肺炎疫情带来了哪些变化？
Eur Heart J Suppl. 2021 Oct 8;23(Suppl E):E161-E167. doi: 10.1093/eurheartj/suab112. eCollection 2021 Oct.
5
A Meta-Analysis of Association between Remdesivir and Mortality among Critically-Ill COVID-19 Patients.瑞德西韦与危重症COVID-19患者死亡率之间关联的Meta分析。
Infect Chemother. 2021 Sep;53(3):512-518. doi: 10.3947/ic.2021.0060. Epub 2021 Aug 30.
6
Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis.中重度 COVID-19 呼吸道疾病的治疗：成本效用分析。
Sci Rep. 2021 Sep 7;11(1):17787. doi: 10.1038/s41598-021-97259-7.
7
One year on: The impact of COVID-19 on clinical research.一年之后：新冠疫情对临床研究的影响
Eur J Intern Med. 2021 Oct;92:24-27. doi: 10.1016/j.ejim.2021.08.008. Epub 2021 Aug 25.
8
Critical Review of the Scientific Evidence and Recommendations in COVID-19 Management Guidelines.对新冠疫情管理指南中科学证据和建议的批判性综述
Open Forum Infect Dis. 2021 Jul 14;8(8):ofab376. doi: 10.1093/ofid/ofab376. eCollection 2021 Aug.
9
Contemporary narrative review of treatment options for COVID-19.当代关于 COVID-19 治疗方法的叙事性综述。
Respirology. 2021 Aug;26(8):745-767. doi: 10.1111/resp.14106. Epub 2021 Jul 8.
10
Quality of and Recommendations for Relevant Clinical Practice Guidelines for COVID-19 Management: A Systematic Review and Critical Appraisal.新型冠状病毒肺炎管理相关临床实践指南的质量与推荐意见：一项系统评价与批判性评估
Front Med (Lausanne). 2021 Jun 10;8:630765. doi: 10.3389/fmed.2021.630765. eCollection 2021.
Zotero 插件